University of Louisville Research Foundation, Inc

Roberto Bolli

Ahmed Abdel-Latif

Janina Ratajczak

Mariusz Z Ratajczak

Magdalena Kucia

Matthew C L Keith

Marcin Wysoczynski

Ewa K Zuba-Surma

Buddhadeb Dawn

Provided are pharmaceutical compositions that include a pharmaceutically acceptable carrier and isolated post-natal cardiac progenitor cells (CPCs) and/or progeny cells thereof that are SSEA3-positive and c-kit-negative. Also provided are methods for preparing cells capable of repairing damaged myocardium, methods for isolating populations of SSEA3-positive/c-kit-negative CPCs from cardiac tissue samples, methods for preparing an isolated cell population enriched in post-natal SSEA3-positive/c-kit-negative CPCs, therapeutic methods for using the presently disclosed cells and populations of cells to treat subjects in need thereof, and cell cultures that contain the presently disclosed cells and populations of cells.

Cardiac progenitor cells and methods of use therefor

The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.

Uses and isolation of stem cells from bone marrow

The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone marrow-derived adherent stem cells for treating tissue and/or organ damage in a subject.

Subpopulations of bone marrow-derived adherent stem cells and methods of use therefor

Growing community of inventors

Louisville, KY, United States of America

Roberto Bolli